Evidence map›Paper›PMID 37046820›Full record

ArticleCancers2023

Towards a Synthesis of the Non-Genetic and Genetic Views of Cancer in Understanding Pancreatic Ductal Adenocarcinoma Initiation and Prevention.

Vishaka Gopalan, Sridhar Hannenhalli

Open access · goldAbstract read
In one paragraph

Article in Cancers, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.2field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 1 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Vishaka GopalanCancer Data Science Laboratory, National Cancer Institute, National Institutes of Health, Bethesda, MD 20814, USA.ORCID 0000-0002-5582-3130
Sridhar HannenhalliCancer Data Science Laboratory, National Cancer Institute, National Institutes of Health, Bethesda, MD 20814, USA.ORCID 0000-0001-9603-7569
National Institutes of Health · US

Funding

Transcriptomic origins of cancerZIABC011964 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI HANNENHALLI, SRIDHAR · 2020 to 2023
$1.8M
NIH HHS Intramural Research Program
6 · The paper itself

Abstract

While much of the research in oncogenesis and cancer therapy has focused on mutations in key cancer driver genes, more recent work suggests a complementary non-genetic paradigm. This paradigm focuses on how transcriptional and phenotypic heterogeneity, even in clonally derived cells, can create sub-populations associated with oncogenesis, metastasis, and therapy resistance. We discuss this complementary paradigm in the context of pancreatic ductal adenocarcinoma. A better understanding of cellular transcriptional heterogeneity and its association with oncogenesis can lead to more effective therapies that prevent tumor initiation and slow progression.

Indexed as

cellular heterogeneityregulatory networkssingle cell omicstherapy resistancetranscriptional heterogeneity

Identifiers

PMID37046820
PMCPMC10093726
OpenAlexW4362671535

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.